PE20060465A1 - Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa - Google Patents
Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coaInfo
- Publication number
- PE20060465A1 PE20060465A1 PE2005000582A PE2005000582A PE20060465A1 PE 20060465 A1 PE20060465 A1 PE 20060465A1 PE 2005000582 A PE2005000582 A PE 2005000582A PE 2005000582 A PE2005000582 A PE 2005000582A PE 20060465 A1 PE20060465 A1 PE 20060465A1
- Authority
- PE
- Peru
- Prior art keywords
- policosanol
- coa
- hmg
- compositions containing
- reductase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE POLICOSANOL Y UN INHIBIDOR DE LA ENZIMA HMG-COA REDUCTASA DE METILGLUTARIL. DICHO POLICOSANOL COMPRENDE UNA MEZCLA DE ALCOHOLES ALIFATICOS PRIMARIOS DE CADENA RECTA CON UN LARGO DE 20 A 36 ATOMOS DE CARBONO, ENTRE LOS CUALES SE ENCUENTRAN 1-EICOSANOL, 1-DOCOSANOL, 1-TETRACOSANOL, ENTRE OTROS. EL INHIBIDOR DE HMG-COA ES UNA ESTATINA TAL COMO LOVASTATIN, ROSUVASTATIN, PRAVASTATIN, ENTRE OTRAS. EL POLICOSANOL Y LA ESTATINA SE ENCUENTRAN EN UNA PROPORCION DE ENTRE 100:1 A 0,01:1 POR PESO. TAMBIEN ESTA REFERIDA A UNA PREPARACION TRANSDERMICA CON LIBERACION SOSTENIDA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES HIPERCOLESTEROLEMICAS, COLESTEROL TOTAL, COLESTEROL LDL, ENFERMEDAD CARDIACA CORONARIA, INFLAMACION, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/853,578 US20050267197A1 (en) | 2004-05-25 | 2004-05-25 | Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060465A1 true PE20060465A1 (es) | 2006-06-12 |
Family
ID=35426221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000582A PE20060465A1 (es) | 2004-05-25 | 2005-05-25 | Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20050267197A1 (es) |
| PE (1) | PE20060465A1 (es) |
| TW (1) | TW200605865A (es) |
| WO (1) | WO2005115381A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272770A1 (en) * | 2004-04-29 | 2005-12-08 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US7183285B2 (en) * | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US7199126B2 (en) * | 2004-04-29 | 2007-04-03 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20050282883A1 (en) * | 2004-04-29 | 2005-12-22 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| MX2007001553A (es) * | 2004-08-06 | 2008-03-07 | Transform Pharmaceuticals Inc | Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados. |
| SG155189A1 (en) * | 2004-08-06 | 2009-09-30 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
| US20060111436A1 (en) * | 2004-11-23 | 2006-05-25 | John Griffin | Compositions and treatments for modulating kinase and/or HMG-CoA reductase |
| WO2006087117A1 (en) * | 2005-02-17 | 2006-08-24 | Chiesi Farmaceutici S.P.A. | Therapeutic combinations of manidi pine and a statin |
| US20070015779A1 (en) * | 2005-04-29 | 2007-01-18 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| PT2018153E (pt) | 2006-04-26 | 2012-07-04 | Rosemont Pharmaceuticals Ltd | Composições orais líquidas |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| US20100178341A1 (en) * | 2008-06-11 | 2010-07-15 | Ranbaxy Laboratories Limited | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US8557236B2 (en) * | 2010-02-09 | 2013-10-15 | Vascure Natural LLC | Cardiovascular support supplement and compositions and methods thereof |
| JP6393037B2 (ja) | 2010-09-15 | 2018-09-19 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcアゴニストの製剤および使用方法 |
| WO2013169797A1 (en) | 2012-05-07 | 2013-11-14 | Omthera Pharmaceuticals, Inc. | Compositions of statins and omega-3 fatty acids |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| CN114903862B (zh) * | 2022-06-15 | 2023-08-22 | 湖北中古生物制药有限公司 | 一种多廿烷醇阿托伐他汀钙复方制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031376A (en) * | 1956-10-11 | 1962-04-24 | Levin | Compositions comprising octacosanol, triacontanol, tetracosanol, or hexacosanol, andmethods employing same |
| US4623667A (en) * | 1985-06-28 | 1986-11-18 | Richardson-Vicks Inc. | Topical treatment of skin inflammatory disorders |
| US4793991A (en) * | 1986-01-31 | 1988-12-27 | Slimak Karen M | Hypoallergenic cosmetics, lip balms and lip sticks |
| US5166156A (en) * | 1989-12-20 | 1992-11-24 | Adir Et Compagnie | Naphthyl piperazines useful as 5-HT1A receptor ligands |
| CU22229A1 (es) * | 1992-09-29 | 1996-01-31 | Dalmer Lab Sa | Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la |
| WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US6596776B2 (en) * | 1999-06-21 | 2003-07-22 | Hauser, Inc. | High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof |
| ES2296711T3 (es) * | 2000-08-03 | 2008-05-01 | Harting, Thomas Francis | Composiciones farmaceuticas y alimenticias que contienen alcoholes de madera o esteroles de madera utiles para rebajar el colesterol del suero. |
| US20030054978A1 (en) * | 2001-08-31 | 2003-03-20 | Babish John G. | Arginine compositions for coordinate modification of multiple cardiovascular risk factors |
| EP1511467A1 (en) * | 2002-06-10 | 2005-03-09 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| US6890941B1 (en) * | 2003-12-03 | 2005-05-10 | Procaps S.A. | Compositions containing HMG Co-A reductase inhibitors and policosanol |
-
2004
- 2004-05-25 US US10/853,578 patent/US20050267197A1/en not_active Abandoned
-
2005
- 2005-05-23 WO PCT/US2005/018186 patent/WO2005115381A2/en not_active Ceased
- 2005-05-24 TW TW094116888A patent/TW200605865A/zh unknown
- 2005-05-25 PE PE2005000582A patent/PE20060465A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005115381A3 (en) | 2007-05-24 |
| TW200605865A (en) | 2006-02-16 |
| US20050267197A1 (en) | 2005-12-01 |
| WO2005115381A2 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060465A1 (es) | Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa | |
| MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
| AR018777A1 (es) | Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo. | |
| ES2721148T3 (es) | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso | |
| ECSP10010433A (es) | Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas | |
| AR040588A1 (es) | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa | |
| PE20080523A1 (es) | Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune | |
| MA29909B1 (fr) | Derives de pyridazine | |
| AR062792A1 (es) | Derivados azetidinona y metodos de uso de estos | |
| SV2011003903A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes | |
| NI200700107A (es) | (bifenil) ácidos carboxílicos y sus derivados | |
| ECSP077275A (es) | Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos | |
| MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
| CR9954A (es) | Derivados de pirazina | |
| CR10452A (es) | Derivados de terfenilo para el tratamiento de enfermedad de alzheimer | |
| PE20000017A1 (es) | Combinaciones de estatina-eter carboxialquilico | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| GT199900081A (es) | Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos. | |
| UY30675A1 (es) | Metodos para el tratamiento de la depresion | |
| PE20060276A1 (es) | Composiciones que contienen policosanol, niaciana y/o derivados de niacina | |
| BRPI0518300A2 (pt) | derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia | |
| BRPI0512964A (pt) | composições para cuidados pessoais com hipossensibilidade melhorada | |
| AR065670A1 (es) | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas | |
| AR076262A1 (es) | Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer | |
| SV2006002089A (es) | Nuevos imidazoles ref. docket 18699 (pc26195a) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |